Dapagliflozin in Living-Donor Kidney Transplant Recipients (NCT07555106)
Effect of Dapagliflozin on Kidney Allograft Function in Living-Donor Kidney Transplant Recipients: A Randomized Open-Label Clinical Trial
🩺 Plain-English Summary (8th-Grade Level)
This randomized, open-label, single-center clinical trial aims to evaluate the effect of dapagliflozin on kidney allograft function in adult recipients of a first living-donor kidney transplant. Participants will be randomized to receive dapagliflozin 10 mg daily starting 4 weeks after transplantation or standard care without SGLT2 inhibitor therapy. The primary outcomes include changes in estimated glomerular filtration rate (eGFR) and albuminuria over 12 months. Secondary outcomes include kidney graft histology findings, oxidative stress biomarkers, cardiovascular parameters, infectious events, and kidney graft survival at 12 months.
Who can join: Review the eligibility criteria below.
Location: Universidad de Guadalajara — Guadalajara, Jalisco
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Universidad de Guadalajara — Guadalajara, Jalisco
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant
- Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study — Pittsburgh, Pennsylvania
- CAR-T Cell Therapy for Desensitization in Kidney Transplantation — Boston, Massachusetts
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation — Birmingham, Alabama
- Social Support Counseling Intervention for Kidney Transplant Candidates — Minneapolis, Minnesota
- Empagliflozin Treatment in Kidney Transplant Recipients — Hines, Illinois
- Phenotype Guided Vasoactive Medication During Kidney Transplantation — Los Angeles, California
Explore by condition: All Kidney Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.